RecruitingNCT07266142

Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma and Non Melanoma Patients. Biobank Huidkanker

Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma and Non Melanoma Patients. Biobank Huidkanker

Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

7,500 participants

Start Date

Nov 17, 2025

Study Type

OBSERVATIONAL

Conditions

Skin Cancer Melanoma Skin Cancer, Non-Melanoma

Summary

The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma and non-melanoma skin cancer. The main questions it aims to answer are: * To create a biobank with samples of human body material (HBM): blood (serum/plasma/DNA) and tissue and clinical data of patients with cutaneous melanoma and non-melanoma. * To support future research questions (after specific approval of the Ethics Committee) by using the biobank (through satellite protocols). If there is a comparison group: Not applicable (umbrella protocol for collection only). Participants will: * Share demographics, medical and surgical history, risk factors. * Complete Cancer Worry Scale questionnaire. * Provide biological samples: * Blood samples (serum, plasma, DNA). * Tissue samples (residual tissue or additional biopsy if consented).

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
Adult subjects (\>18 years of age) at time of enrolment.
Subjects diagnosed with cutaneous melanoma or Non-melanoma skin cancer.
Adult subjects able and willing to provide informed consent.